# Aclaris Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aclaris-therapeutics

- Industry: Biotechnology
- Headquarters: Wayne, US
- Website: www.aclaristx.com
- Total disclosed funding: $82M
- Latest round: Series C (Sep 9, 2015)
- Investors on record: 8

## About

Founded in 2012 and based in Pennslyvania, US, Aclaris Therapeutics, Inc. operates as a biotechnology company that develops small molecule therapies for patients suffering from immuno-inflammatory conditions. The company also operates Confluence Discovery Technologies, Inc. as an indirect, wholly-owned subsidiary that provides full-service drug discovery and early development services for pharma and biotech companies. In October 2015, Aclaris Therapeutics, Inc. was listed on the Nasdaq under the symbol ACRS for an initial public offering of 5 million shares priced at USD 11 apiece. In November 2024, Aclaris Therapeutics, Inc. raised USD 80 million in PPIPE funding led by returning investor Vivo Capital, with participation from new Rock Springs Capital, Adage Capital Management, Decheng Capital, Logos Capital, and Samsara BioCapital. Other returning investors Forge Life Science Partners, RA Capital Management, and other unspecified investors also participated in the round. As part of the transaction, the company agreed to sell 35.5 million shares of common stock purchase at USD 4.9 per share, for gross proceeds of approximately USD 80 million.

The company's R&D (research and development) team utilizes KINect, a drug discovery platform that enables the generation of diversified immuno-inflammatory therapeutics to attach human kinases with adenosine triphosphate (ATP) site cysteines (human cysteinome) for the treatment of patients with aesthetic, medical dermatology, and immuno-inflammatory diseases. In October 2019, EPI Health acquired RHOFADE, an oxymetazoline hydrochloride cream for rosacea from Aclaris Therapeutics, Inc.

As a contract research organization, the company's revenue is generated by providing research partnership and development services of specialty pharmaceuticals for biotechnology companies. The company revenue growth rate decreased by 58.11 percent from USD 10.09 million in FY 2018 to USD 4.23 million in FY 2019.

The company continues to develop a multi-state portfolio of drug candidates through KINect, the R&D engine exploring protein kinase regulation for the potential treatment of immuno-inflammatory diseases, such as the oral approach on moderate to severe RA (Rheumatoid Arthritis).

## Funding rounds

- Series C, Sep 9, 2015, $40M — Sofinnova Investments, Aperture Venture Partners, Vivo Capital, F-Prime Capital, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, Mossrock Capital
- Series B, Sep 30, 2014, $21M — Sofinnova Investments, Vivo Capital, F-Prime Capital
- Series A, Aug 30, 2012, $21M — Sofinnova Investments, Vivo Capital, F-Prime Capital

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B, Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B, Series C
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Mossrock Capital (https://capitalatlas.ai/funds/mossrock-capital) — Series C